NZ589269A - Combination therapy with an antitumor alkaloid - Google Patents
Combination therapy with an antitumor alkaloidInfo
- Publication number
- NZ589269A NZ589269A NZ589269A NZ58926909A NZ589269A NZ 589269 A NZ589269 A NZ 589269A NZ 589269 A NZ589269 A NZ 589269A NZ 58926909 A NZ58926909 A NZ 58926909A NZ 589269 A NZ589269 A NZ 589269A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- antitumor
- inhibitors
- carcinoma
- combination therapy
- Prior art date
Links
- 239000003976 antineoplastic alkaloid Substances 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 102000003915 DNA Topoisomerases Human genes 0.000 abstract 1
- 108090000323 DNA Topoisomerases Proteins 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010035603 Pleural mesothelioma Diseases 0.000 abstract 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 abstract 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 abstract 1
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 201000001531 bladder carcinoma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 208000010749 gastric carcinoma Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000498 stomach carcinoma Diseases 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5372608P | 2008-05-16 | 2008-05-16 | |
| PCT/US2009/044334 WO2009140675A2 (en) | 2008-05-16 | 2009-05-18 | Combination therapy with an antitumor alkaloid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ589269A true NZ589269A (en) | 2013-03-28 |
Family
ID=41136781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ589269A NZ589269A (en) | 2008-05-16 | 2009-05-18 | Combination therapy with an antitumor alkaloid |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110070232A1 (https=) |
| EP (1) | EP2307003A2 (https=) |
| JP (1) | JP2011520921A (https=) |
| KR (1) | KR20110025178A (https=) |
| CN (1) | CN102099025A (https=) |
| AU (1) | AU2009246130A1 (https=) |
| CA (1) | CA2724325A1 (https=) |
| IL (1) | IL209361A0 (https=) |
| MX (1) | MX2010012501A (https=) |
| NZ (1) | NZ589269A (https=) |
| RU (1) | RU2010151602A (https=) |
| WO (1) | WO2009140675A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7919493B2 (en) | 2000-04-12 | 2011-04-05 | Pharma Mar, S.A. | Anititumoral ecteinascidin derivatives |
| MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| GB0117402D0 (en) | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
| GB0202544D0 (en) | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
| WO2011048210A1 (en) | 2009-10-22 | 2011-04-28 | Pharma Mar, S.A. | PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT |
| ME02395B (me) * | 2010-11-12 | 2016-09-20 | Pharma Mar Sa | Kombinovana terapija sa antitumorskim alkaloidima |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| ES3057783T3 (en) * | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| HRP20231233T1 (hr) | 2017-04-27 | 2024-01-19 | Pharma Mar, S.A. | Antitumorski spojevi |
| KR102260846B1 (ko) | 2018-07-09 | 2021-06-07 | 국립암센터 | 고시폴, 펜포르민 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| JP2023503318A (ja) | 2019-11-21 | 2023-01-27 | ファルマ、マール、ソシエダード、アノニマ | ルルビネクテジン製剤で小細胞肺がんを処置する方法 |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997027848A1 (en) * | 1996-01-31 | 1997-08-07 | Board Of Regents, The University Of Texas System | SENSITIZATION OF HER2/neu OVER-EXPRESSING CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS |
| ATE265847T1 (de) * | 1997-07-29 | 2004-05-15 | Upjohn Co | Selbstemulgierbare formulierung enthaltend lipophile verbindungen |
| AU770309B2 (en) * | 1998-06-05 | 2004-02-19 | Regent Court Technologies | Monoamine oxidase (MAO) inhibitors and uses thereof |
| US6124292A (en) * | 1998-09-30 | 2000-09-26 | President And Fellows Of Harvard College | Synthetic analogs of ecteinascidin-743 |
| MY130271A (en) * | 1999-05-14 | 2007-06-29 | Pharma Mar Sa | Hemisynthetic method and new compounds |
| JP2003520801A (ja) * | 2000-01-19 | 2003-07-08 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成 |
| MXPA02011319A (es) * | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| GB0229793D0 (en) * | 2002-12-20 | 2003-01-29 | Pharma Mar Sa | The gene cluster involved in safracin biosynthesis and its uses for genetic engineering |
| AU2005333515B2 (en) * | 2004-07-09 | 2012-05-10 | Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona | Wortmannin analogs and methods of using same in combination with chemotherapeutic agents |
| GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| CA2636596A1 (en) * | 2005-11-04 | 2007-05-18 | James Pluda | Method of treating cancers with saha and pemetrexed |
| JP2009514870A (ja) * | 2005-11-04 | 2009-04-09 | ワイス | ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ |
| KR101108407B1 (ko) * | 2006-06-21 | 2012-01-30 | 일라이 릴리 앤드 캄파니 | 젬시타빈 아미드 전구약물의 결정 형태, 그의 조성물 및 용도 |
| CA2724206A1 (en) * | 2008-05-16 | 2009-11-19 | Pharma Mar S.A. | Multiple myeloma treatments |
-
2009
- 2009-05-18 CA CA2724325A patent/CA2724325A1/en not_active Abandoned
- 2009-05-18 MX MX2010012501A patent/MX2010012501A/es not_active Application Discontinuation
- 2009-05-18 EP EP09747756A patent/EP2307003A2/en not_active Withdrawn
- 2009-05-18 RU RU2010151602/15A patent/RU2010151602A/ru not_active Application Discontinuation
- 2009-05-18 JP JP2011509790A patent/JP2011520921A/ja active Pending
- 2009-05-18 NZ NZ589269A patent/NZ589269A/xx not_active IP Right Cessation
- 2009-05-18 US US12/992,812 patent/US20110070232A1/en not_active Abandoned
- 2009-05-18 CN CN2009801276302A patent/CN102099025A/zh active Pending
- 2009-05-18 AU AU2009246130A patent/AU2009246130A1/en not_active Abandoned
- 2009-05-18 WO PCT/US2009/044334 patent/WO2009140675A2/en not_active Ceased
- 2009-05-18 KR KR1020107028378A patent/KR20110025178A/ko not_active Withdrawn
-
2010
- 2010-11-16 IL IL209361A patent/IL209361A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102099025A (zh) | 2011-06-15 |
| WO2009140675A3 (en) | 2010-04-01 |
| CA2724325A1 (en) | 2009-11-19 |
| KR20110025178A (ko) | 2011-03-09 |
| RU2010151602A (ru) | 2012-06-27 |
| IL209361A0 (en) | 2011-01-31 |
| EP2307003A2 (en) | 2011-04-13 |
| US20110070232A1 (en) | 2011-03-24 |
| AU2009246130A1 (en) | 2009-11-19 |
| JP2011520921A (ja) | 2011-07-21 |
| MX2010012501A (es) | 2010-12-20 |
| WO2009140675A2 (en) | 2009-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ589269A (en) | Combination therapy with an antitumor alkaloid | |
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| Usmani et al. | 17 AAG for HSP90 inhibition in cancer-from bench to bedside | |
| NZ580009A (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| JP2009501141A5 (ja) | 骨腫瘍の治療のための抗igf-ir抗体 | |
| RU2014128513A (ru) | Раковый маркер и терапевтическая мишень | |
| WO2008094321A3 (en) | Akt sensitization of cancer cells | |
| MX2018012457A (es) | Terapia combinatoria con inhibidores notch y cdk4/6. | |
| MX378263B (es) | Terapia de combinación para el tratamiento del cáncer. | |
| IL299099B1 (en) | Combinations of cancer treatments | |
| AU2011274510A8 (en) | Combinations of kinase inhibitors for the treatment of cancer | |
| MX2010009156A (es) | Terapia de combinacion 238. | |
| CL2011001445A1 (es) | Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias | |
| MX2022009612A (es) | Combinacion de bi853520 con farmacos quimioterapeuticos. | |
| WO2012065085A4 (en) | Methods of treating cancer | |
| RU2018138626A (ru) | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака | |
| TW201613589A (en) | Combination methods for treating cancers | |
| TNSN07294A1 (en) | Treatment of metastasized tumors | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| MX2025003936A (es) | Combinacion de talazoparib y enzalutamida en el tratamiento del cancer de prostata metastasico resistente a la castracion | |
| NZ596861A (en) | Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer | |
| NZ596226A (en) | Antitumor combination including cabazitaxel and capecitabine | |
| MX2023000008A (es) | Inhibidor de fgfr y mutacion, metodo de preparacion y uso del mismo. | |
| WO2024040045A3 (en) | 2-diarylmethyl-4-aminotetrahydropyran sulfonimidamides as anticancer, antiinflammatory, antifibrotic and neuroprotective agents | |
| WO2014115859A3 (ja) | 分子標的併用腫瘍治療・予防薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 MAY 2016 BY SHELSTON IP Effective date: 20130718 |
|
| LAPS | Patent lapsed |